 |
|
A Double-blind Study of the Effectiveness of Cyclosporine in Amyotrophic Lateral Sclerosis
Stanley H. Appel, MD;
S. Scott Stewart, MD;
Vicki Appel, RN;
Yadollah Harati, MD;
William Mietlowski, PhD;
William Weiss;
George W. Belendiuk, MD, PhD
Arch Neurol. 1988;45(4):381-386.
Abstract
• In a double-blind placebo-controlled trial of cyclosporine in amyotrophic lateral sclerosis, no differences were observed in the monthly rate of progression or the relative risk of progression in comparing 38 patients randomized to the placebo group and 36 patients randomized to the cyclosporine group. In comparing three subgroups of patients, cyclosporine appeared to benefit men who entered the study within 18 months of the onset of first symptoms, whereas it was of no value to women or to men who entered later than 18 months. For the men with recent onset of disease, the relative risk of progression was 0.403; the monthly rate of progression was 5.2 ± 1.1 points with placebo and 3.5 ± 0.7 points with cyclosporine. These provocative results support the need for a full study of cyclosporine in men with recent onset of disease.
Author Affiliations
From the Department of Neurology, Baylor College of Medicine (Drs Appel, Stewart, and Harati, and Ms Appel) and the Veterans Administration Medical Center (Drs Stewart and Harati), Houston; and the Sandoz Research Institute (Drs Mietlowski and Belendiuk), Hanover, NJ. Mr Weiss is in statistical consulting in Vienna, Va.
Footnotes
Accepted for publication Dec 8, 1987.
Reprint requests to Department of Neurology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030 (Dr S. Appel).
 CiteULike  Connotea  Delicious  Digg  Facebook  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Cytochrome c Association with the Inner Mitochondrial Membrane Is Impaired in the CNS of G93A-SOD1 Mice
Kirkinezos et al.
J. Neurosci. 2005;25:164-172.
ABSTRACT
| FULL TEXT
Selegiline Is Ineffective in a Collaborative Double-blind, Placebo-Controlled Trial for Treatment of Amyotrophic Lateral Sclerosis
Lange et al.
Arch Neurol 1998;55:93-96.
ABSTRACT
| FULL TEXT
Therapeutic Considerations in Patients With Refractory Neurosarcoidosis
Agbogu et al.
Arch Neurol 1995;52:875-879.
ABSTRACT
Effect of High-Dose Intravenous Immunoglobulin on Amyotrophic Lateral Sclerosis and Multifocal Motor Neuropathy
Dalakas et al.
Arch Neurol 1994;51:861-864.
ABSTRACT
The Treatment of Neurosarcoidosis With Cyclosporine
Stern et al.
Arch Neurol 1992;49:1065-1072.
ABSTRACT
Misdiagnosis in Patients With Amyotrophic Lateral Sclerosis
Belsh and Schiffman
Arch Intern Med 1990;150:2301-2305.
ABSTRACT
|
